Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2023-02-06 00:00:00 ET · period of report 2023-02-02 · accession 0001567619-23-001929 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-06 | 2023-02-02 | CTMX | Landau Jeffrey B | Chief Business Off | A - Grant | $0.00 | +40.0K | 70.7K | +130% | $0 |
| DM | 2023-02-06 | 2023-02-02 | CTMX | Landau Jeffrey B | Chief Business Off | A - Grant | $0.00 | +175.0K | 75.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-02 | A | A | 40,000 | $0.00 | 70,725 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date. (F2) Includes 56,274 RSUs. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-02 | A | A | 100,000 | $0.00 | 100,000 | D | $2.59 · — to 2033-02-01 | 100,000 Common Stock | (F3) 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing as a service provider through each such date. |
| 3 | Derivative | Performance Stock Units (PSUs) | 2023-02-02 | A | A | 75,000 | $0.00 | 75,000 | D | — · — to — | 75,000 Common Stock | (F4) Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. |